- Home
- UFCS vs OPT Comparison
UFCS vs OPT Comparison
Compare UFCS & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- OPT
- Stock Information
- Founded
- UFCS 1946
- OPT 1984
- Country
- UFCS United States
- OPT Australia
- Employees
- UFCS N/A
- OPT N/A
- Industry
- UFCS Property-Casualty Insurers
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFCS Finance
- OPT Health Care
- Exchange
- UFCS Nasdaq
- OPT Nasdaq
- Market Cap
- UFCS 642.7M
- OPT 767.9M
- IPO Year
- UFCS N/A
- OPT 2020
- Fundamental
- Price
- UFCS $28.95
- OPT $3.25
- Analyst Decision
- UFCS Hold
- OPT Strong Buy
- Analyst Count
- UFCS 1
- OPT 1
- Target Price
- UFCS $26.00
- OPT $12.00
- AVG Volume (30 Days)
- UFCS 114.1K
- OPT 38.5K
- Earning Date
- UFCS 11-05-2024
- OPT 08-30-2024
- Dividend Yield
- UFCS 2.34%
- OPT N/A
- EPS Growth
- UFCS N/A
- OPT N/A
- EPS
- UFCS 1.94
- OPT N/A
- Revenue
- UFCS $1,207,451,000.00
- OPT $261,859.00
- Revenue This Year
- UFCS N/A
- OPT N/A
- Revenue Next Year
- UFCS $9.19
- OPT $46,864.64
- P/E Ratio
- UFCS $14.06
- OPT N/A
- Revenue Growth
- UFCS 10.95
- OPT N/A
- 52 Week Low
- UFCS $18.04
- OPT $1.79
- 52 Week High
- UFCS $27.69
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- UFCS 80.36
- OPT 30.64
- Support Level
- UFCS $24.62
- OPT $3.22
- Resistance Level
- UFCS $27.69
- OPT $3.37
- Average True Range (ATR)
- UFCS 0.98
- OPT 0.19
- MACD
- UFCS 0.49
- OPT -0.10
- Stochastic Oscillator
- UFCS 99.83
- OPT 14.17
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.